Vials produced by Gerresheimer are displayed at the annual Drug, Chemical & Associated Technologies Association (DCAT) week in New York City, U.S. March 19, 2024. REUTERS/Patrick Wingrove/File Photo Purchase Licensing Rights, opens new tab
CompaniesMUNICH, March 20 (Reuters) - U.S. packaging company Silgan Holdings (SLGN.N), opens new tab has signalled interest in taking over German medical packaging maker Gerresheimer <GXIG.DE, opens new tab, according to two sources familiar with the matter.
Silgan is working with advisers on the approach that could value Gerresheimer at 41 euros per share, one source said, cautioning that there is no certainty there will be a bid and that a transaction will be completed.
Get a look at the day ahead in U.S. and global markets with the Morning Bid U.S. newsletter. Sign up here.
Gerresheimer declined to comment.
Silgan was not immediately available for comment.
Gerresheimer shares rose 6.7% following the news to trade at 18.9 euros.
Gerresheimer, worth about 600 million euros ($694 million), has seen its shares drop more than 80% from its 2023 peak and the stock is down 37% since the start of the year.
The company said in late February that Germany's financial regulator BaFin is widening a probe into its financial statements, adding pressure on the medical products maker as it grapples with accounting issues and a plunging share price.
The Duesseldorf-based company held talks last year with private equity investors over a potential sale, but the conversations ended without an agreement.
($1 = 0.8644 euros)
Reporting by Alexander Huebner in Munich, Christoph Steitz in Frankfurt; Additional reporting by Milana Vinn in New York; writting by Andres Gonzalez; Editing by Miranda Murray and Louise Heavens
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Silgan Holdings delivered robust 2025 results, with revenue up over 10% and EBIT rising 15% to nearly $600 million, driven by the Weener Plastics acquisition. SLGN generated about $400 million in free cash flow, comfortably covering its dividend and supporting rapid net debt reduction, despite net debt standing at 3.5x EBITDA. Guidance for 2026 targets $450 million in free cash flow and adjusted EPS of $3.7–$3.9, with a $500 million buyback program activated but not yet utilized.
Vials produced by Gerresheimer are displayed at the annual Drug, Chemical & Associated Technologies Association (DCAT) week in New York City, U.S. March 19, 2024. REUTERS/Patrick Wingrove/File... Purchase Licensing Rights, opens new tab Read more
CompaniesMUNICH, April 17 (Reuters) - German medical packaging maker Gerresheimer (GXIG.DE), opens new tab has rejected a takeover bid from its U.S. rival Silgan (SLGN.N), opens new tab, three sources familiar with the situation told Reuters.
There are no longer any talks between the two companies, according to the sources.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Shares in Gerresheimer were down 5.4% on the news before paring losses and swinging slightly into positive territory.
One source said that Gerresheimer wants to focus for now on resolving its accounting problems and selling its U.S. subsidiary Centor.
Reuters reported in March that Silgan had signalled an interest in taking over Gerresheimer with a non-binding offer of 41 euros ($48.31) per share, more than double the current share price.
A Gerresheimer spokesperson said the company does not comment on market rumours. Silgan did not respond to a request for comment.
($1 = 0.8488 euros)
Reporting by Alexander Huebner, Christoph Steitz and Anneli Palmen, writing by Miranda Murray and Linda Pasquini, editing by Friederike Heine and Thomas Seythal
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Silgan (SLGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crown Holdings (CCK - Free Report) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.67 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +6.17%. A quarter ago, it was expected that this packaging company would post earnings of $1.69 per share when it actually produced earnings of $1.74, delivering a surprise of +2.96%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Crown, which belongs to the Zacks Containers - Metal and Glass industry, posted revenues of $3.26 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 8.10%. This compares to year-ago revenues of $2.89 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Crown shares have lost about 1.8% since the beginning of the year versus the S&P 500's gain of 4.7%.
What's Next for Crown?While Crown has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Crown was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.23 on $3.27 billion in revenues for the coming quarter and $8.03 on $12.77 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Containers - Metal and Glass is currently in the bottom 5% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Silgan Holdings (SLGN - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 29.
This packaging products supplier is expected to post quarterly earnings of $0.74 per share in its upcoming report, which represents a year-over-year change of -9.8%. The consensus EPS estimate for the quarter has been revised 6.1% lower over the last 30 days to the current level.
Silgan Holdings' revenues are expected to be $1.49 billion, up 1.8% from the year-ago quarter.
Silgan Holdings (SLGN - Free Report) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.19%. A quarter ago, it was expected that this packaging products supplier would post earnings of $0.65 per share when it actually produced earnings of $0.67, delivering a surprise of +3.08%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Silgan, which belongs to the Zacks Containers - Metal and Glass industry, posted revenues of $1.56 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.53%. This compares to year-ago revenues of $1.47 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Silgan shares have lost about 3.9% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Silgan?While Silgan has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Silgan was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.97 on $1.58 billion in revenues for the coming quarter and $3.73 on $6.65 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Containers - Metal and Glass is currently in the bottom 6% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Ball (BALL - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.
This metal packaging company is expected to post quarterly earnings of $0.85 per share in its upcoming report, which represents a year-over-year change of +11.8%. The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level.
Ball's revenues are expected to be $3.27 billion, up 5.7% from the year-ago quarter.
Although the revenue and EPS for Silgan (SLGN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NORWALK, Conn.--(BUSINESS WIRE)--Silgan Holdings Inc. (NYSE: SLGN), a leading supplier of sustainable rigid packaging solutions for the world's essential consumer goods products, announced today that its Board of Directors declared a quarterly cash dividend on its common stock. The Board of Directors approved a $0.21 per share quarterly cash dividend payable on June 15, 2026 to the holders of record of common stock of the Company on June 1, 2026. With this dividend payment, the Company will have paid a quarterly cash dividend on its common stock, which it has increased every year, for eighty-nine consecutive quarters since 2004.
* * *
Silgan is a leading supplier of sustainable rigid packaging solutions for the world's essential consumer goods products with annual net sales of approximately $6.5 billion in 2025. Silgan operates 121 manufacturing facilities in North and South America, Europe and Asia. The Company is a leading worldwide supplier of dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products. The Company is also a leading supplier of metal containers in North America and Europe for pet and human food and general line products. In addition, the Company is a leading supplier of custom containers for shelf-stable food and personal care products in North America.
A month has gone by since the last earnings report for Silgan Holdings (SLGN - Free Report) . Shares have lost about 6.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Silgan due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
Silgan Q1 Earnings Beat Estimates, Revenues Rise Y/YSilgan Holdings reported adjusted earnings of 78 cents per share in the first quarter 2026, beating the Zacks Consensus Estimate of 74 cents by 5.4%. The bottom line decreased 4.9% year over year.
Including one-time items, earnings were 60 cents per share compared with 63 cents in the prior-year quarter.
Total revenues increased year over year to $1.56 billion from the prior-year quarter’s $1.47 billion. The top line beat the Zacks Consensus Estimate of $1.49 billion by 4.5%.
SLGN’s Q1 Costs & MarginsIn first-quarter 2026, the cost of goods sold increased 8.3% year over year to around $1.3 billion. The gross profit decreased 1.7% to $265.8 million. The gross margin was 17% compared with the prior-year quarter’s 18.4%.
Selling, general and administrative expenses amounted to $131.2 million, up 1.6% year over year. The company reported an adjusted operating income of $152 million compared with $158.3 million in the prior-year quarter. The operating margin was 9.7%, down from the prior-year quarter’s 10.8%.
Silgan Holdings’ Q1 Segment PerformancesRevenues in the Dispensing and Specialty Closures segment rose 2% year over year to $685.3 million. Results were driven by the contractual pass-through of higher raw material and other costs and favorable foreign currency translation, which helped offset the weather-related impact on production.
The adjusted EBITDA for the segment was $136.8 million, up 1.3% from $135.1 million in the first quarter of 2025. Segment adjusted EBIT fell 3% to $96.1 million due to less favorable volume and mix and less favorable price/cost, including inventory effects in its European metal closures operations.
The Metal Containers segment’s revenues improved 15% year over year to $724.9 million due to improved price/mix resulting from contractual pass-through of higher raw material and other manufacturing costs and higher volumes. The segment’s adjusted EBITDA was $69.8 million compared with $68.8 million in the prior-year quarter. Adjusted EBIT edged up 0.4% to $49.8 million from $49.6 million, driven by higher volumes, partly offset by weaker pricing and product mix in certain markets.
In the Custom Containers segment, revenues totaled $151.1 million, down 9.6% from $167.2 million in the year-ago quarter, primarily due to lower volumes. Volumes bore the impact of the company’s decision to exit businesses with lower margins in 2025 as part of Silgan’s footprint optimization plans. The segment reported an adjusted EBITDA of $29.7 million, down from the prior-year quarter’s $33.3 million. Segment adjusted EBIT declined to $21.7 million from $24.6 million, mainly due to lower sales volumes.
SLGN’s Cash Flow & Cash PositionThe company had cash and cash equivalents of $435.4 million at the end of the first quarter of 2026, compared with $353 million at the end of the first quarter of 2025. SLGN used $799.6 million of cash in operating activities in the first quarter of 2026 compared with $683.4 million in the prior-year period. Capital expenditures for the reported quarter were $82.4 million.
Silgan Holdings’ 2Q & 2026 OutlookThe company increased its adjusted earnings per share guidance to $3.73-$3.93 for 2026, indicating a 3% year-over-year increase at the midpoint. For second-quarter 2026, SLGN anticipates adjusted EPS to be between 92 cents and $1.02. It posted EPS of $1.01 in the year-ago quarter.
How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.
VGM ScoresAt this time, Silgan has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Charting a somewhat similar path, the stock has a score of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Silgan has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Commvault between April 29, 2025 and January 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 10, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT) and reminds investors of the July 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - June 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against CommVault Systems, Inc. (NASDAQ: CVLT) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired CommVault securities between April 29, 2025 and January 26, 2026, both dates inclusive (the "Class Period").
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 17, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Commvault Systems Inc. (“Commvault” or the “Company”) (NASDAQ: CVLT) securities between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”).
IF YOU SUFFERED A LOSS ON YOUR COMMVAULT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
What Happened?
On January 27, 2026, Commvault published third quarter 2026 fiscal results, including annualized recurring revenue (“ARR”) of 22% and a total net new ARR was $39 million, falling short of the prior quarter’s guidance for $45 million of net new ARR for the quarter. Management revealed in the accompanying earnings call that the variation was due to product mix, including increased SaaS deals in the quarter.
On this news, Commvault’s stock price fell $40.23, or 31.1%, to close at $89.13 per share on January 27, 2026, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Commvault knew or recklessly disregarded the impact that different types of sales would have on its ARR growth; (2) the variation in net ARR growth is strongly based on the type of sale Commvault is making, thus, the Company’s projected net new ARR should not have been determined without properly factoring in sale type; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Commvault securities during the Class Period, you may move the Court no later than July 17, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
SAN FRANCISCO, June 10, 2026 (GLOBE NEWSWIRE) -- Commvault Systems, Inc. (NASDAQ: CVLT) faces a securities class action lawsuit, which seeks to represent investors who purchased or otherwise acquired Commvault securities between April 29, 2025 and January 26, 2026. The lawsuit follows the massive 31% collapse in the company shares on January 27, 2026, triggered by the company's Q3 2026 financial results that included a significant shortfall in certain critical financial metrics.
San Diego, California--(Newsfile Corp. - June 10, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Commvault Systems, Inc. (NASDAQ: CVLT) securities between April 29, 2025 and January 26, 2026, both dates inclusive (the "Class Period"), have until Friday, July 17, 2026 to seek appointment as lead plaintiff of the Commvault class action lawsuit. Captioned Imbert v.
NEW YORK, June 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), of the important July 17, 2026 lead plaintiff deadline. So what: If you purchased Commvault securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CVLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 17, 2026.
SAN FRANCISCO, June 11, 2026 /PRNewswire/ -- Commvault Systems, Inc. (NASDAQ: CVLT) faces a securities class action lawsuit, which seeks to represent investors who purchased or otherwise acquired Commvault securities between April 29, 2025 and January 26, 2026. Hagens Berman is investigating the pending claims alleging Commvault's pre-January 27 disclosures violated the federal securities laws.
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA in the Commvault Systems Securities Action Where Investors Lost $40.23 Per Share After Alleged ARR Guidance Failures NEW YORK, June 11, 2026 /PRNewswire/ -- IMPORTANT DATE: July 17, 2026. Investors who purchased Commvault Systems, Inc. (NASDAQ: CVLT) securities between April 29, 2025 and January 26, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date.
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
New York, New York--(Newsfile Corp. - June 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), of the important July 17, 2026 lead plaintiff deadline. SO WHAT: If you purchased Commvault securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Commvault between April 29, 2025 and January 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT) and reminds investors of the July 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options
LOS ANGELES, June 12, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Commvault Systems, Inc. (“Commvault” or “the Company”) (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 17, 2026.
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). Shareholders who purchased shares of CVLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Commvault Systems, Inc. (NASDAQ: CVLT) faces a securities class action lawsuit, which seeks to represent investors who purchased or otherwise acquired Commvault securities between April 29, 2025 and January 26, 2026. The lawsuit follows the massive 31% collapse in the company shares on January 27, 2026, triggered by the company's Q3 2026 financial results that included a significant shortfall in certain critical financial metrics.
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn.
United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST, at the RBC Capital Markets Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An.
/PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and demonstrated reduced risk of a clinical worsening event, meeting both its primary endpoint and a key secondary endpoint with statistical significance, respectively
In combined analyses of TETON-1 and TETON-2 — also included in the NEJM publication and presented at ATS — nebulized Tyvaso achieved statistically significant treatment effects across the primary and most secondary efficacy endpoints
Nebulized Tyvaso combines direct lung delivery with multi-modal activity across fibrotic, vascular, and inflammatory pathways that are not currently addressed by existing IPF therapies
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. The use of nebulized Tyvaso for IPF has not been approved by the U.S. Food and Drug Administration (FDA) and remains investigational for IPF.
The results of TETON-1 were also presented at ATS during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session on Sunday, May 17. Combined results from TETON-1 and TETON-2 were presented today during an oral session at ATS.
TETON-1 met its primary efficacy endpoint, with nebulized Tyvaso demonstrating statistically significant improvement in absolute FVC relative to placebo from baseline to week 52 in an IPF population broadly treated with background therapy. The median change in FVC at week 52 was −43.3 mL (95% confidence interval [CI], −92.1 to −9.1) in the nebulized Tyvaso group and −196.2 mL (95% CI, −227.1 to −155.6) in the placebo group; between-group difference was 130.1 mL (95% CI, 82.2 to 178.1; P<0.001).
Nebulized Tyvaso reduced the risk of a clinical worsening event by 33% (hazard ratio [HR], 0.67; 95% CI, 0.52 to 0.88; P=0.0034) relative to placebo, a statistically significant improvement in this key secondary endpoint. Nebulized Tyvaso showed numerical improvement in other important secondary endpoints, including improved change in percent of predicted FVC, King’s Brief Interstitial Lung Disease quality of life questionnaire (K-BILD), and change in percent of predicted diffusion capacity of lungs for carbon monoxide (DLCO).
Benefits of nebulized Tyvaso in TETON-1 were observed across all subgroups, including use of background therapy (nintedanib, pirfenidone, or no background therapy), smoking status, and supplemental oxygen use.
Combined analyses of TETON-1 and TETON-2 showed that nebulized Tyvaso achieved statistically significant treatment effects compared to placebo from baseline to week 52 for the primary endpoint and for most key secondary endpoints.
The median change in FVC at 52 weeks in the combined data set was −45.4 mL (95% CI, −73.8 to −23.1) in the nebulized Tyvaso group and −161.7 mL (95% CI, −194.5 to −134.1) in the placebo arm; between-group difference was 111.8 mL (95% CI, 79.7 to 144; P<0.0001).
Nebulized Tyvaso reduced the risk of a clinical worsening event in the combined data set by 31% (HR: 0.69; 95% CI, 0.57 to 0.84; P=0.0002) and the risk of acute IPF exacerbation by 48% (HR: 0.52; 95% CI, 0.30 to 0.91; P=0.0223) relative to placebo. Nebulized Tyvaso also achieved statistically significant improvements in changes in percent predicted FVC, K-BILD score, and DLCO. Overall survival at week 52 trended in favor of Tyvaso but did not meet statistical significance.
“The results of TETON-1 validate what was seen in TETON-2. The combined analysis provides an incredibly powerful dataset with both studies complementing each other well. The meaningful effect on FVC decline observed across all subgroups, as well as achieving positive results for five out of six secondary endpoints in the combined analysis, is truly impressive for a 52-week treatment duration. These findings have the potential to fundamentally impact how we target IPF and manage patients living with this devastating disease. Speaking on behalf of the steering committee, we are incredibly grateful to all the investigators, research coordinators, and most importantly, to all the patients who participated. Their willingness to participate epitomizes taking the fight back to the disease,” said Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and Chair of the TETON Steering Committee.
“The profound impact of the TETON clinical program in IPF, with combined results showing significantly improved preservation of lung function and quality of life, as well as reductions in disease worsening and acute IPF exacerbations, represents a truly important advancement for people living with this progressive, life-threatening disease,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “We are incredibly proud that our rigorous clinical trials and their unprecedented results continue to receive prestigious recognition from a high caliber journal like The New England Journal of Medicine and from ATS leadership.”
“Nebulized Tyvaso combines direct lung delivery with multimodal activity across fibrotic, vascular, and inflammatory pathways that are not currently addressed by existing IPF therapies. The unprecedented results of our TETON clinical program — in which nebulized Tyvaso achieved statistical significance in endpoints never before attained in other IPF clinical trials — support the importance of this differentiated, multi-pathway activity,” said Peter Smith, Pharm.D., Senior Vice President, Product Development at United Therapeutics and the lead for the global TETON program.
United Therapeutics plans to seek priority review of a supplemental New Drug Application, to be submitted to the FDA by the end of this summer, to add IPF to the labeled indications for nebulized Tyvaso based on data from the TETON-1 and TETON-2 studies. Both the FDA and the European Medicines Agency have granted orphan designation for treprostinil to treat IPF.
Full results of the TETON-2 study were also recently published in the New England Journal of Medicine and are available online at NEJM.org.
TETON Clinical Program
A post-hoc analysis of the INCREASE study in patients with pulmonary hypertension associated with interstitial lung disease suggested that nebulized Tyvaso was associated with a significant improvement in FVC, laying the foundation for the TETON clinical program to evaluate the use of nebulized Tyvaso in IPF and progressive pulmonary fibrosis (PPF). TETON-1 enrolled patients with IPF in the United States and Canada, and TETON-2 enrolled patients with IPF outside the United States and Canada. TETON-PPF is evaluating the use of nebulized Tyvaso in PPF in patients globally, and enrollment is ongoing.
The use of nebulized Tyvaso for IPF and PPF has not been approved by the FDA and remains investigational.
TETON-1 Study Design
The TETON-1 study (NCT04708782) was a 598-patient, multicenter, randomized, double-blind, placebo-controlled phase 3 registration study evaluating the safety and efficacy of nebulized Tyvaso in patients with IPF over a 52-week period at sites in the United States and Canada. The study reached full enrollment in January 2025.
The primary endpoint of the study was the change in absolute FVC from baseline to week 52. Secondary endpoints included: (1) time to clinical worsening; (2) time to first acute exacerbation of IPF; (3) overall survival at week 52; (4) change in percent predicted FVC from baseline to week 52; (5) change in the K-BILD questionnaire from baseline to week 52; and (6) change in DLCO from baseline to week 52.
Safety assessments included the development of adverse events, serious adverse events, vital signs, clinical laboratory parameters, and electrocardiogram parameters.
Eligible patients completing the TETON-1 study could enroll in the TETON-OLE study (NCT04905693), an ongoing open-label extension study to evaluate the long-term safety and tolerability of nebulized Tyvaso in patients with fibrotic lung disease.
About IPF
Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown (idiopathic) cause and is the most common of the idiopathic interstitial pneumonias. IPF is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. While the precise causes of IPF remain unknown, IPF rarely presents before age 50 and can be associated with cigarette smoking and certain genetic dispositions. In addition, some evidence suggests that gastroesophageal reflux (acid reflux, or heartburn), certain viral infections, air pollution, and workplace exposures may be risk factors for IPF. IPF is estimated to affect between 0.33 and 4.51 people per 10,000 persons worldwide. Further, United Therapeutics estimates there are over 100,000 IPF patients in the United States.
About Tyvaso® (treprostinil) Inhalation Solution
INDICATION
TYVASO (treprostinil) Inhalation Solution is a prostacyclin mimetic indicated for the treatment of:
Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with TYVASO establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with TYVASO establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.
TYVASO inhibits platelet aggregation and increases the risk of bleeding.
Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.
Like other inhaled prostaglandins, TYVASO may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with TYVASO.
DRUG INTERACTIONS/SPECIFIC POPULATIONS
The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
Safety and effectiveness in pediatric patients have not been established.
Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.
ADVERSE REACTIONS
Pulmonary Arterial Hypertension (WHO Group 1)
In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.
Pulmonary Hypertension Associated with ILD (WHO Group 3)
In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions with TYVASO were similar to the experience in studies of PAH.
Please see Full Prescribing Information for TYVASO, the TD-300 TYVASO® Inhalation System Instructions for Use manual, and additional information at www.TYVASOHCP.com or call 1 844 UNITHER (1-844-864-8437).
About United Therapeutics
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the timing and anticipated outcome of our planned regulatory submission to the FDA to seek approval to add IPF to the labeled indications for nebulized Tyvaso, including our plan to seek priority review; our expectations concerning the potential benefits of nebulized Tyvaso for IPF patients, including the potential to fundamentally impact how physicians target IPF and manage patients living with this devastating disease; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of May 18, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
TYVASO is a registered trademark of United Therapeutics Corporation.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST, at the Jefferies Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archive.
While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons made a prodigious investment in the memory company as far back as 2013 – when it was trading at approximately $18 – and saw the equity rise almost exactly 5,000% since.
Over the years, the billionaire’s Renaissance Technologies made multiple adjustments to the position, meaning he did not see the entire return from the initial bet, but given MU shares, performance in recent months, it is nonetheless significantly ‘in the money.’
Specifically, Jim Simons’ fund increased its investment in Micron by 151% in the fourth quarter (Q4) of 2025 by acquiring nearly $660 million worth of the stock. At the time, the memory giant was trading in the range between approximately $180 and $300.
At press time on May 29, and after a 223.58% year-to-date (YTD) rally, MU is changing hands at $923.52. Therefore, the position reported as worth $859 million at the end of 2025 would have risen to $2.77 billion in just five months had the investor not reduced the stake by 21% in Q1.
Micron stock price YTD chart. Source: Finbold Still, the subsequent 13-F filing – the one covering Q1 2026 – shows that Micron was Renaissance’s fifth-largest portfolio holding, and Finbold decided to examine its fortunes with the largest four positions.
Jim Simons’ Kinross Gold stock investment Renaissance Technologies first began developing its fourth-largest – as of the most recent filing – position, Kinross Gold Corp (NYSE: KGC), as far back as 2013, when the shares were trading at roughly $5.82.
In the fund’s typical fashion, there were multiple balance changes, and the most recent substantial purchase that was not succeeded by a comparable sale came during the first three months of 2026 at an average quarterly price of $34.02.
Considering that KCG stock is, at press time on May 29, changing hands at $29.29, Simons could be up 403% relative to the initial buy, but might be 14% in the red on the most recent purchase.
KGC stock price all-time chart. Source: Google Jim Simons’ Apple stock investment The situation would have been significantly better regarding the third-largest portfolio position – Apple (NASDAQ: AAPL) – had the billionaire held the original, 2013 stake, likely acquired at an average price of $15.38.
Indeed, AAPL shares have rallied 1,920% to $310.66 since then, but, notably, Simons’ fund reestablished the holding only in Q1 2026 – after clearing it during the previous year – at approximately $260.16, indicating he is still in the green, albeit by a relatively limited 19.41%.
Apple stock price one-year chart. Source: Finbold Jim Simons’ Palantir stock investment Thanks to the extensive trading and its relative recency, the performance of Renaissance Technologies’ Palantir (NASDAQ: PLTR) is somewhat more difficult to gauge, though it is evident the billionaire has profited overall from the bet on the firm, given it was, at the end of Q1 2026, the second-biggest portfolio holding.
Jim Simons made his first PLTR purchases at roughly $24 toward the middle of 2021, and his most recent significant buy was at about $180.80 and executed during the final three months of the previous year.
Palantir shares themselves are, at press time on May 29, changing hands at $146.77, meaning they soared 511% relative to the taking of the original position but fell 18.82% relative to the most recent known buys.
Palantir stock price one-year chart. Source: Finbold Jim Simons’ United Therapeutics stock investment Lastly, Jim Simons largest stock position – accounting for 1.7% of the 3,213-stock portfolio relative to Micron’s 1.1% – is undeniably up compared to the original likely average purchase price of $64.42 in 2013 and the most recent, Q3 2025, of $335.18.
United Therapeutics stock price YTD chart. Source: Finbold Indeed, having risen 13.16% year-to-date (YTD) to $565.50, United Therapeutics Corp (NASDAQ: UTHR) is 777.83% above the value at the time the original stake was built, and 68.72% above where it stood during the latest increase.
